Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PIP's Cash to Debt is ranked higher than
96% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. PIP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PIP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 6.42 Max: No Debt
Current: No Debt
Equity to Asset 0.87
PIP's Equity to Asset is ranked higher than
78% of the 698 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PIP: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
PIP' s Equity to Asset Range Over the Past 10 Years
Min: -0.53  Med: 0.57 Max: 0.87
Current: 0.87
-0.53
0.87
F-Score: 5
Z-Score: 21.69
M-Score: -0.48
WACC vs ROIC
17.30%
-548.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -78.72
PIP's Operating margin (%) is ranked higher than
51% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. PIP: -78.72 )
Ranked among companies with meaningful Operating margin (%) only.
PIP' s Operating margin (%) Range Over the Past 10 Years
Min: -873.96  Med: -97.15 Max: -24.89
Current: -78.72
-873.96
-24.89
Net-margin (%) 76.79
PIP's Net-margin (%) is ranked higher than
98% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. PIP: 76.79 )
Ranked among companies with meaningful Net-margin (%) only.
PIP' s Net-margin (%) Range Over the Past 10 Years
Min: -909.98  Med: -95.24 Max: 76.79
Current: 76.79
-909.98
76.79
ROE (%) 22.99
PIP's ROE (%) is ranked higher than
94% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -32.34 vs. PIP: 22.99 )
Ranked among companies with meaningful ROE (%) only.
PIP' s ROE (%) Range Over the Past 10 Years
Min: -453.67  Med: -76.43 Max: 22.99
Current: 22.99
-453.67
22.99
ROA (%) 19.33
PIP's ROA (%) is ranked higher than
96% of the 955 Companies
in the Global Biotechnology industry.

( Industry Median: -27.67 vs. PIP: 19.33 )
Ranked among companies with meaningful ROA (%) only.
PIP' s ROA (%) Range Over the Past 10 Years
Min: -111.46  Med: -43.29 Max: 19.33
Current: 19.33
-111.46
19.33
ROC (Joel Greenblatt) (%) -1863.68
PIP's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: -358.44 vs. PIP: -1863.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PIP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2862.64  Med: -281.39 Max: -39.54
Current: -1863.68
-2862.64
-39.54
Revenue Growth (3Y)(%) -31.70
PIP's Revenue Growth (3Y)(%) is ranked lower than
80% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. PIP: -31.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PIP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.7  Med: -27.1 Max: 173.6
Current: -31.7
-31.7
173.6
EBITDA Growth (3Y)(%) -25.40
PIP's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. PIP: -25.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PIP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.7  Med: -33.7 Max: 36.4
Current: -25.4
-66.7
36.4
EPS Growth (3Y)(%) -20.60
PIP's EPS Growth (3Y)(%) is ranked lower than
69% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -3.60 vs. PIP: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PIP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.7  Med: -40.3 Max: 28.6
Current: -20.6
-68.7
28.6
» PIP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

PIP Guru Trades in Q3 2014

Louis Moore Bacon 50,000 sh (New)
» More
Q4 2014

PIP Guru Trades in Q4 2014

Louis Moore Bacon 50,000 sh (unchged)
» More
Q1 2015

PIP Guru Trades in Q1 2015

Louis Moore Bacon Sold Out
» More
Q2 2016

PIP Guru Trades in Q2 2016

Jim Simons 149,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CASC, NAS:RDHL, NAS:VTL, OTCPK:SPHRY, NAS:CYAD, NAS:RGLS, NAS:KMDA, NAS:EGLT, NAS:MRUS, NAS:ARGS, NAS:CARA, NAS:PRQR, NAS:OCUL, OTCPK:MXDHF, NAS:STML, NAS:MDWD, NAS:QURE, NAS:CDXS, AMEX:MDGN, NAS:ADVM » details
Traded in other countries:3G0.Germany,
PharmAthene Inc is a biodefense company. It is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States.

PharmAthene Inc was incorporated under the laws of the State of Delaware on April 25, 2005. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), and the National Institute of Health (NIH). Its competitors include Emergent BioSolutions, Inc., Green Cross, Panacea Biotec Ltd., and PaxVax, among others. The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.

Ratios

vs
industry
vs
history
P/E(ttm) 48.17
PIP's P/E(ttm) is ranked lower than
65% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 28.59 vs. PIP: 48.17 )
Ranked among companies with meaningful P/E(ttm) only.
PIP' s P/E(ttm) Range Over the Past 10 Years
Min: 12.15  Med: 42.33 Max: 156.6
Current: 48.17
12.15
156.6
PE(NRI) 48.17
PIP's PE(NRI) is ranked lower than
64% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 28.70 vs. PIP: 48.17 )
Ranked among companies with meaningful PE(NRI) only.
PIP' s PE(NRI) Range Over the Past 10 Years
Min: 12.38  Med: 42.33 Max: 138.33
Current: 48.17
12.38
138.33
Price/Owner Earnings (ttm) 60.21
PIP's Price/Owner Earnings (ttm) is ranked lower than
64% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 31.24 vs. PIP: 60.21 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PIP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 45  Med: 52.92 Max: 60.21
Current: 60.21
45
60.21
P/B 7.73
PIP's P/B is ranked lower than
75% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. PIP: 7.73 )
Ranked among companies with meaningful P/B only.
PIP' s P/B Range Over the Past 10 Years
Min: 1.3  Med: 5.84 Max: 31.07
Current: 7.73
1.3
31.07
P/S 33.60
PIP's P/S is ranked lower than
71% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. PIP: 33.60 )
Ranked among companies with meaningful P/S only.
PIP' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 3.27 Max: 82.18
Current: 33.6
0.41
82.18
PFCF 35.68
PIP's PFCF is ranked lower than
59% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 28.24 vs. PIP: 35.68 )
Ranked among companies with meaningful PFCF only.
PIP' s PFCF Range Over the Past 10 Years
Min: 26.67  Med: 33.58 Max: 356
Current: 35.68
26.67
356
POCF 48.17
PIP's POCF is ranked lower than
71% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 22.40 vs. PIP: 48.17 )
Ranked among companies with meaningful POCF only.
PIP' s POCF Range Over the Past 10 Years
Min: 36  Med: 44.83 Max: 72.17
Current: 48.17
36
72.17
EV-to-EBIT -38.16
PIP's EV-to-EBIT is ranked lower than
99.99% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 23.08 vs. PIP: -38.16 )
Ranked among companies with meaningful EV-to-EBIT only.
PIP' s EV-to-EBIT Range Over the Past 10 Years
Min: -38.16  Med: -6.4 Max: 127.1
Current: -38.16
-38.16
127.1
EV-to-EBITDA -39.47
PIP's EV-to-EBITDA is ranked lower than
99.99% of the 258 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. PIP: -39.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
PIP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.47  Med: -7.3 Max: 127.1
Current: -39.47
-39.47
127.1
Current Ratio 7.77
PIP's Current Ratio is ranked higher than
69% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.42 vs. PIP: 7.77 )
Ranked among companies with meaningful Current Ratio only.
PIP' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.85 Max: 389.51
Current: 7.77
0.41
389.51
Quick Ratio 7.77
PIP's Quick Ratio is ranked higher than
70% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.19 vs. PIP: 7.77 )
Ranked among companies with meaningful Quick Ratio only.
PIP' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.85 Max: 389.51
Current: 7.77
0.41
389.51
Days Sales Outstanding 67.47
PIP's Days Sales Outstanding is ranked lower than
54% of the 586 Companies
in the Global Biotechnology industry.

( Industry Median: 62.03 vs. PIP: 67.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
PIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.98  Med: 54.35 Max: 319.57
Current: 67.47
3.98
319.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.00
PIP's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. PIP: -10.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PIP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.2  Med: -21.45 Max: -4.2
Current: -10
-34.2
-4.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.63
PIP's Price/Net Cash is ranked lower than
63% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 5.92 vs. PIP: 9.63 )
Ranked among companies with meaningful Price/Net Cash only.
PIP' s Price/Net Cash Range Over the Past 10 Years
Min: 3.26  Med: 14.11 Max: 186
Current: 9.63
3.26
186
Price/Net Current Asset Value 8.50
PIP's Price/Net Current Asset Value is ranked lower than
62% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. PIP: 8.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PIP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 7.34 Max: 73.33
Current: 8.5
1.48
73.33
Price/Tangible Book 8.55
PIP's Price/Tangible Book is ranked lower than
70% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. PIP: 8.55 )
Ranked among companies with meaningful Price/Tangible Book only.
PIP' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.48  Med: 6.96 Max: 35.7
Current: 8.55
1.48
35.7
Price/Projected FCF 41.29
PIP's Price/Projected FCF is ranked lower than
92% of the 161 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. PIP: 41.29 )
Ranked among companies with meaningful Price/Projected FCF only.
PIP' s Price/Projected FCF Range Over the Past 10 Years
Min: 34.86  Med: 34.86 Max: 41.29
Current: 41.29
34.86
41.29
Price/Median PS Value 10.32
PIP's Price/Median PS Value is ranked lower than
96% of the 615 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. PIP: 10.32 )
Ranked among companies with meaningful Price/Median PS Value only.
PIP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1 Max: 24.85
Current: 10.32
0.2
24.85
Price/Graham Number 4.25
PIP's Price/Graham Number is ranked lower than
63% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. PIP: 4.25 )
Ranked among companies with meaningful Price/Graham Number only.
PIP' s Price/Graham Number Range Over the Past 10 Years
Min: 1.14  Med: 3.08 Max: 4.25
Current: 4.25
1.14
4.25
Earnings Yield (Greenblatt) (%) -2.60
PIP's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: -8.80 vs. PIP: -2.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PIP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.6  Med: 0.85 Max: 2239
Current: -2.6
-2.6
2239

More Statistics

Revenue (TTM) (Mil) $5.54
EPS (TTM) $ 0.06
Beta2.09
Short Percentage of Float3.94%
52-Week Range $1.20 - 2.92
Shares Outstanding (Mil)65.59
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
PharmAthene Announces Receipt of Payments from SIGA Sep 16 2016
PharmAthene Announces Receipt of Payments from SIGA Sep 16 2016
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process Aug 25 2016
PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process Aug 25 2016
PHARMATHENE, INC Financials Aug 12 2016
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process Aug 05 2016
PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process Aug 05 2016
PHARMATHENE, INC Files SEC form 10-Q, Quarterly Report Aug 04 2016
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2016
PharmAthene Reports Second Quarter 2016 Financial and Operational Results Aug 04 2016
PharmAthene Reports Second Quarter 2016 Financial and Operational Results Aug 04 2016
ETF’s with exposure to PharmAthene, Inc. : July 26, 2016 Jul 26 2016
PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline Jul 08 2016
PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline Jul 08 2016
ETF’s with exposure to PharmAthene, Inc. : July 1, 2016 Jul 01 2016
PharmAthene to Join Russell 3000® and Global Indexes Jun 23 2016
PharmAthene to Join Russell 3000® and Global Indexes Jun 23 2016
PHARMATHENE, INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 07 2016
ETF’s with exposure to PharmAthene, Inc. : May 27, 2016 May 26 2016
PharmAthene, Inc. :PIP-US: Earnings Analysis: Q1, 2016 By the Numbers : May 24, 2016 May 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)